期刊
MABS
卷 2, 期 2, 页码 148-156出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.2.2.11159
关键词
monoclonal; polyclonal; induction; transplants; kidney; lung; liver; heart; rejection; complications
Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential, benefits of the therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据